Centessa Pharmaceuticals (CNTA) Current Assets (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Current Assets data on file, last reported at $348.7 million in Q1 2026.

• Current Assets for Q1 2026 came in at $348.7 million, changed 0.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $348.7 million (changed 0.28% YoY), and the FY2025 annual result was $367.9 million, down 31.42% from the prior year.
• Current Assets retreated to $348.7 million in Q1 2026 per CNTA's latest filing, from $367.9 million in the prior quarter.
• Over five years, Current Assets peaked at $581.2 million in Q1 2022 and troughed at $284.5 million in Q1 2024.
• A 5-year average of $400.9 million and a median of $355.5 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets soared 70.96% in 2024, then plunged 45.87% in 2025.
• A 5-year view of Current Assets shows it stood at $437.7 million in 2022, then fell by 28.02% to $315.1 million in 2023, then surged by 70.24% to $536.4 million in 2024, then plunged by 31.42% to $367.9 million in 2025, then declined by 5.22% to $348.7 million in 2026.
• Business Quant data shows CNTA's Current Assets at $348.7 million in Q1 2026, $367.9 million in Q4 2025, and $307.7 million in Q3 2025.